SMS Pharmaceuticals has received revision in credit ratings from CARE Ratings as under:Long term bank facilities (Rs 350.87 crore) - CARE A; Positive (reaffirmed, outlook revised from Stable) Short term bank facilities (Rs 52.83 crore) - CARE A1 (upgraded from CARE A2+) Powered by Capital Market - Live News

SMS Pharmaceuticals announced that the US Food and Drug Administration has approved its associate company VKT Pharma`s reformulated Ranitidine tablets in 150mg and 300mg strengths. This approval marks the re-entry of this important acid-reducing medication into the US market after a five-year absence. The approval by the US FDA comes after extensive safety testing and manufacturing improvements that address previous concerns regarding the formation of NDMA impurity. It is expected to increase patient access to this important medication for patients who rely on it for various health conditions. Powered by Capital Market - Live News

Net profit of SMS Pharmaceuticals rose 79.50% to Rs 25.31 crore in the quarter ended September 2025 as against Rs 14.10 crore during the previous quarter ended September 2024. Sales rose 23.22% to Rs 242.43 crore in the quarter ended September 2025 as against Rs 196.75 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales242.43196.75 23 OPM %19.9515.99 - PBDT44.0628.16 56 PBT34.0419.54 74 NP25.3114.10 80 Powered by Capital Market - Live News

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 November 2025.Powered by Capital Market - Live News

SMS Pharmaceuticals announced that the 37th Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live News